How Is The COVID-19 Vaccination Campaign Going In Your State?
The U.S. is engaged in a massive effort to vaccinate the bulk of its population against COVID-19. But some states are working faster than others. See how yours is faring.
Related Articles
Should Patients with COVID-19 Who Are at Standard Risk Take Nirmatrelvir/Ritonavir?
U.S. National Institutes of Health guidelines currently recommend nirmatrelvir/ritonavir (Paxlovid) as first-line therapy for outpatients with COVID-19
Sexually Transmitted Infections—A Closer Look at NIAID Research
Sexually transmitted infections (STIs) are caused by bacteria, viruses, or parasites. NIAID supports research across the spectrum from basic to clinical science to develop effective…
Case Series Examining the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial – CROI Conference
Background: Long-acting antiretroviral therapy (LA-ART) is novel and has been used for both virologically-suppressed (VS) and viremic patients with adherence challenges. The currently-approved LA-ART combination…
Aid ‘still not reaching Gaza’, as top US official warns famine has started
Samantha Power becomes first US official to confirm famine, while aid workers decry continuing lack of help
Inactivated Whole Virus Particle Influenza Vaccine Induces Anti-Neuraminidase Antibodies That May Contribute to Cross-Protection against Heterologous Virus Infection
Despite the use of vaccines, seasonal influenza remains a risk to public health. We previously proposed the inactivated whole virus particle vaccine (WPV) as an…
Pfizer RSV shot meets goals in trial of high-risk adults under age 60
Pfizer said on Tuesday its respiratory syncytial virus (RSV) vaccine Abrysvo was well tolerated and generated an immune response in higher risk adults under the…
2nd Annual Pandemic Preparedness Symposium
Pandemic Preparedness Symposium: Antiviral Medicines for the Next Big Threat
High Frequency of Prior SARS-CoV-2 Infection by Sensitive Nucleocapsid Assays
We show that the Simoa and intracellular cytokine staining SARS-CoV-2 nucleocapsid assays are more sensitive than the clinical Elecsys assay. These data su
Reporter’s Notebook: The Epidemic She Didn’t Expect to See
Four years after the COVID-19 lockdown in San Francisco, an interview with Dr. Monica Gandhi, author of “Endemic: A Post Pandemic Playbook.”
To Prepare for the Next Pandemic, Let’s Not Forget the Last One
It seems that San Francisco, and maybe the United States, wants to move on from COVID-19. But remembering is how we’ll prevent future tragedy.